As we rush headlong into virtual worlds in the metaverse, the concept of digital twins will become more and more conspicuous.

We first got word of Midnight Ghost Hunt way back in June of 2019, sending a chill of excitement up our spines. Its developer, Vaulted Sky Games, was looking to recharge the ghost-hunting and prop-hunting genres — at pretty much the same time. One could describe Midnight Ghost Hunt as a Ghostbusters-meets-PropHunt game, and that’s not far off the mark. The game has received alpha and beta tests, but I hadn’t tried my hand at it until just recently. I was able to jump in for a hands-on preview of Midnight Ghost Hunt, and had a spooky good time. Midnight Ghost Hunt is a team-based, four-on-four multiplayer game. It sees a group of weapon- and gadget-wielding hunters facing off against some feisty poltergeists. But don’t think that the game paces itself like Phasmophobia; the heavily armed hunters are on the clock, and only have until midnight to clean house.   The conceit is in the game’s name. Hunters have until midnight to discover and subdue the g...

Vibrant country style and patterns abound in the Pioneer Woman's newest collection for Walmart.

Twitter took a further leap into the world of crypto by adding NFT profile picture verification for certain users via OpenSea's API.

PlayStation creator Ken Kutaragi isn't very fond of VR/AR headsets... In a recent interview he called them "simply annoying".

As the novel coronavirus epidemic continues to spread across the globe, WTR provides an updated look at measures that national IP offices have launched in response.

Just jammin’.

Bull Empire is a Solana-based collection composed of 2,500 pixelized bulls, each possessing unique traits and different levels of rarity.  It seems that Asian folklore is making a big splash this year and making itself known to the world through non-fungible token (NFT) collections. With impressive artworks, passionate teams, and exciting roadmaps, Asian-themed NFTs are starting […]

The post What is Bull Empire? appeared first on Asia Crypto Today.

A new packaging format provides extreme silicon area density versus package volume.

The post Thin Quad Die Package (QDP) Development appeared first on Semiconductor Engineering.

The post New Feature in Quest Update Could Bolster WebXR Use appeared first on Road to VR.

The Swedish team welcomes their first all-women squad and Luminosity refreshes their 2022 roster

Click here to read the full article.

TOKYO, Jan 20, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine. The pivotal study evaluated the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. versus chemotherapy (treatment of physician's choice of doxorubicin or paclitaxel) for patients with advanced endometrial carcinoma following at-least one prior platinum-based regimen in any setting.

The publication includes previously reported data that was first presented in an oral plenary session at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer.(1) Results showed that the LENVIMA plus KEYTRUDA combination demonstrated statistically significant improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Objective response rate (ORR) data and additional detailed efficacy and safety data, including subgroup analyses, are also featured in the publication.

"While rates of endometrial carcinoma continue to rise globally, patients with advanced or recurrent disease have limited options available to them once the disease progresses following platinum-based chemotherapy," said Dr. Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck Research Laboratories. "KEYNOTE-775/Study 309 is an important Phase 3 study that supported recent approvals of KEYTRUDA plus LENVIMA for certain types of advanced endometrial carcinoma in the U.S. and other countries around the world, where it became the first immunotherapy and tyrosine kinase inhibitor combination approved for these patients."

"The Phase 3 Study 309/KEYNOTE-775 trial demonstrates the ongoing commitment that Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. share in addressing the unmet needs of people living with difficult-to-treat cancers, including advanced endometrial carcinoma," said Corina Dutcus, M.D., Senior Vice President, Clinical Research, Oncology Business Group at Eisai Inc. "The publication of this study in the New England Journal of Medicine reflects the importance of our joint research in exploring the potential of the LENVIMA plus KEYTRUDA combination."

The publication contains results for the all-comer population, including the mismatch repair deficient (dMMR) patient population for which LENVIMA plus KEYTRUDA is not approved in the U.S.

Based on the results from the Phase 3 Study 309/KEYNOTE-775 trial, LENVIMA plus KEYTRUDA has been approved in the U.S. for patients with advanced endometrial carcinoma that is not microsatellite instability-high or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. LENVIMA plus KEYTRUDA is also approved in the European Union and Japan for certain patients with advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in more than 10 different tumor types across more than 20 clinical trials.

(1) Eisai co., Ltd. Home page. "LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study". https://www.eisai.com/news/2021/news202116.html

Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
Investor Relations:
+81-(0) 70-8688-9685

Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Media Relations
Melissa Moody: +1-(215) 407-3536
Nikki Sullivan: +1-(718) 644-0730
Investor Relations
Peter Dannenbaum: +1- (908) 740-1037
Raychel Kruper: +1-(908) 740- 2107

For more information, visit https://www.eisai.com/news/2022/news202207.html.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine.